|
|
 Previous Article | Table of Contents | Next Article 
Evidence that essential thrombocythemia is a clonal disorder with origin in
a multipotent stem cell
PJ Fialkow, GB Faguet, RJ Jacobson, K Vaidya and S Murphy
Essential thrombocythemia is characterized by proliferation of
hematopoietic tissue predominantly involving megakaryocytes and resulting
in marked thrombocytosis. The disorder has some clinical and laboratory
features that resemble those seen in the clonal multipotent stem cell
disorders chronic myelogenous leukemia, polycythemia vera, and agnogenic
myeloid metaplasia. It has been argued that essential thrombocythemia
should be classified together with those disorders as a myeloproliferative
syndrome. However, without knowledge of the numbers and types of cells that
are involved in essential thrombocythemia, this suggestion remains
speculative. Three patients with thrombocytosis were studied. The diagnosis
of essential thrombocythemia was considered to be firm in two patients and
probable in the third one. The X-linked glucose-6-phosphate dehydrogenase
locus was used as a cell marker. Whereas both A and B types of
glucose-6-phosphate dehydrogenase were found in nonhematopoietic tissues,
only a single-enzyme type was found in the granulocytes, red cells, and
platelets from each patient. These data indicate that the disorders in
these three patients are clonal and involve multipotent stem cells.
Volume 58,
Issue 5,
pp. 916-919,
11/01/1981
Copyright © 1981 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Thiele
Philadelphia Chromosome-Negative Chronic Myeloproliferative Disease
Am J Clin Pathol,
August 1, 2009;
132(2):
261 - 280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, P. Guglielmelli, and A. Tefferi
Advances in Understanding and Management of Myeloproliferative Neoplasms
CA Cancer J Clin,
May 1, 2009;
59(3):
171 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Spivak and R. T. Silver
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
Blood,
July 15, 2008;
112(2):
231 - 239.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. James
The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases?
Hematology,
January 1, 2008;
2008(1):
69 - 75.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chaligne, C. James, C. Tonetti, R. Besancenot, J. P. Le Couedic, F. Fava, F. Mazurier, I. Godin, K. Maloum, F. Larbret, et al.
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis
Blood,
November 15, 2007;
110(10):
3735 - 3743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Skoda
The Genetic Basis of Myeloproliferative Disorders
Hematology,
January 1, 2007;
2007(1):
1 - 10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Delhommeau, S. Dupont, C. Tonetti, A. Masse, I. Godin, J.-P. L. Couedic, N. Debili, P. Saulnier, N. Casadevall, W. Vainchenker, et al.
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis
Blood,
January 1, 2007;
109(1):
71 - 77.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Campbell and A. R. Green
The Myeloproliferative Disorders
N. Engl. J. Med.,
December 7, 2006;
355(23):
2452 - 2466.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ishii, E. Bruno, R. Hoffman, and M. Xu
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
Blood,
November 1, 2006;
108(9):
3128 - 3134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kralovics, S.-S. Teo, S. Li, A. Theocharides, A. S. Buser, A. Tichelli, and R. C. Skoda
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
Blood,
August 15, 2006;
108(4):
1377 - 1380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Levine and G. Wernig
Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders
Hematology,
January 1, 2006;
2006(1):
233 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-S. Chim, Y.-L. Kwong, A. K.-W. Lie, S.-K. Ma, C.-C. Chan, L.-G. Wong, B. C. San Kho, H.-K. Lee, J. P.-Y. Sim, C.-H. Chan, et al.
Long-term Outcome of 231 Patients With Essential Thrombocythemia: Prognostic Factors for Thrombosis, Bleeding, Myelofibrosis, and Leukemia
Arch Intern Med,
December 12, 2005;
165(22):
2651 - 2658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Pathogenesis of Myelofibrosis With Myeloid Metaplasia
J. Clin. Oncol.,
November 20, 2005;
23(33):
8520 - 8530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi and T. Barbui
bcr/abl-Negative, Classic Myeloproliferative Disorders: Diagnosis and Treatment
Mayo Clin. Proc.,
September 1, 2005;
80(9):
1220 - 1232.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Tefferi and D. G. Gilliland
The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis
Mayo Clin. Proc.,
July 1, 2005;
80(7):
947 - 958.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Liu, J. Jelinek, Y. D. Pastore, Y. Guan, J. F. Prchal, and J. T. Prchal
Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin
Blood,
April 15, 2003;
101(8):
3294 - 3301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Reeder, R. J. Bailey, G. W. Dewald, and A. Tefferi
Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia
Blood,
March 1, 2003;
101(5):
1981 - 1983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Polycythemia Vera: A Comprehensive Review and Clinical Recommendations
Mayo Clin. Proc.,
February 1, 2003;
78(2):
174 - 194.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L.-Y. Shih, T.-L. Lin, C.-L. Lai, P. Dunn, J.-H. Wu, P.-N. Wang, M.-C. Kuo, and L.-C. Lee
Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia
Blood,
August 13, 2002;
100(5):
1596 - 1601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Rameshwar, D. D. Joshi, P. Yadav, J. Qian, P. Gascon, V. T. Chang, D. Anjaria, J. S. Harrison, and X. Song
Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fibrosis
Blood,
May 15, 2001;
97(10):
3025 - 3031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Vickers, E. McLeod, T. D. Spector, and I. J. Wilson
Assessment of mechanism of acquired skewed X inactivation by analysis of twins
Blood,
March 1, 2001;
97(5):
1274 - 1281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Axelrad, D. Eskinazi, P. N. Correa, and D. Amato
Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia
Blood,
November 15, 2000;
96(10):
3310 - 3321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Klippel, E. Strunck, S. Roder, M. Lubbert, W. Lange, M. Azemar, G. Meinhardt, H.-E. Schaefer, and H. L. Pahl
Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera
Blood,
April 15, 2000;
95(8):
2569 - 2576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Harrison, R. E. Gale, S. J. Machin, and D. C. Linch
A Large Proportion of Patients With a Diagnosis of Essential Thrombocythemia Do Not Have a Clonal Disorder and May Be at Lower Risk of Thrombotic Complications
Blood,
January 15, 1999;
93(2):
417 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Randi, F. Fabris, G. Cella, C. Rossi, and A. Girolami
Cerebral Vascular Accidents in Young Patients with Essential Thrombocythemia: Relation with Other Known Cardiovascular Risk Factors
Angiology,
June 1, 1998;
49(6):
477 - 481.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. R. Moliterno, W. D. Hankins, and J. L. Spivak
Impaired Expression of the Thrombopoietin Receptor by Platelets from Patients with Polycythemia Vera
N. Engl. J. Med.,
February 26, 1998;
338(9):
572 - 580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Sterkers, C. Preudhomme, J.-L. Lai, J.-L. Demory, M.-T. Caulier, E. Wattel, D. Bordessoule, F. Bauters, and P. Fenaux
Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Cases With 17p Deletion
Blood,
January 15, 1998;
91(2):
616 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. El Kassar, G. Hetet, J. Briere, and B. Grandchamp
X-Chromosome inactivation in healthy females: incidence of excessive lyonization with age and comparison of assays involving DNA methylation and transcript polymorphisms
Clin. Chem.,
January 1, 1998;
44(1):
61 - 67.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Horikawa, I. Matsumura, K. Hashimoto, M. Shiraga, S. Kosugi, S. Tadokoro, T. Kato, H. Miyazaki, Y. Tomiyama, Y. Kurata, et al.
Markedly Reduced Expression of Platelet c-mpl Receptor in Essential Thrombocythemia
Blood,
November 15, 1997;
90(10):
4031 - 4038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Blickstein, A. Aviram, J. Luboshitz, M. Prokocimer, P. Stark, O. Bairey, J. Sulkes, and M. Shaklai
BCR-ABL Transcripts in Bone Marrow Aspirates of Philadelphia-Negative Essential Thrombocythemia Patients: Clinical Presentation
Blood,
October 1, 1997;
90(7):
2768 - 2771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. El-Kassar, G. Hetet, J. Briere, and B. Grandchamp
Clonality Analysis of Hematopoiesis in Essential Thrombocythemia: Advantages of Studying T Lymphocytes and Platelets
Blood,
January 1, 1997;
89(1):
128 - 134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Spitzer and N. L. Harris
Case 31-1993- A 49-Year-Old Man with Myelofibrosis, Myeloid Metaplasia, and Osteolytic Lesions of the Left Femur
N. Engl. J. Med.,
August 5, 1993;
329(6):
417 - 423.
[Full Text]
|
|
|
|
|
